knowledge -WSS

knowledge

author：leisure time 2025-09-27 10:00:16 - browse：5478

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Yancopoulos of Regeneron works to expand Dupixent success

leisure time

WSS

Pfizer, Moderna say biotech, pharma drug development is a sprint

Yancopoulos of Regeneron works to expand Dupixent success

Yancopoulos of Regeneron works to expand Dupixent success

Asbestos ban is immediate, but health effects will linger for decades

iTeos Therapeutics debuts first data on TIGIT

Biotech investment managers search for lucrative opportunities

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

The cancer drug shortage isn’t new — and neither are the solutions

Antibiotic resistance nearly killed me, so I'm raising awareness of it

In age of alternative facts, a scholarly course on calling out crap

Adam's Take: Intra

Moonlake's readout produced a cash windfall. Risks remain

Medical devices makers are asking for forgiveness, not permission

After affirmative action ruling, medical educators look to 'holistic review'

Dark money group runs ads on China biotech bill

hotspot

Biohaven protein

Bring on the sabbaticals for nurses

Texas board proposes rules on abortion law emergency exemption

Addiction doctors spar with methadone clinics over legislation

Insmed lung disease drug hits target in key Phase 3 trial

Medicare Advantage insurers pressure Biden for bigger payments

hotspot

leisure time

hotspot

focus